Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
Nanjing Leads tests investor appetite for Lag3
But BeOne canned its alcestobart deal in May.
